ABEO vs BEAM
ABEO: Abeona is a commercial-stage biopharmaceutical company that just received FDA approval for ZEVASKYN®, the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) wounds. BEAM: Beam Therapeutics is developing base editing medicines—a precision genetic cure approach—for serious inherited diseases like sickle cell disease and rare genetic disorders.
Side-by-side fundamentals
| Metric | ABEO | BEAM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.42 | $26.64 | |
| Market cap as of 2026-07-23 | $374M | $2.7B | |
| P/E as of 2026-07-23 | 5.66 | n/a | |
| Net margin as of 2026-07-23 | +490.4% | -39.7% | ABEO higher |
| Gross margin as of 2026-07-23 | +73.5% | n/a | |
| Operating margin as of 2026-07-23 | +575.2% | -226.6% | ABEO higher |
| ROE as of 2026-07-23 | +41.4% | -5.9% | ABEO higher |
| ROA as of 2026-07-23 | +29.5% | -4.6% | ABEO higher |
| Debt / equity as of 2026-07-23 | 0.12 | 0.09 | BEAM lower |
| Revenue growth (YoY) as of 2026-07-23 | +60.4% | +158.0% | BEAM higher |
| Revenue CAGR (3y) SEC XBRL | +18.0% | +31.9% | BEAM higher |
| Beta as of 2026-07-23 | 1.33 | 2.22 | |
| 1-year return as of 2026-07-22 close | -1.5% | +29.8% | BEAM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.